Reversal of multidrug resistance of gastric cancer cells by down-regulation of ZNRD1 with ZNRD1 siRNA

Br J Biomed Sci. 2004;61(4):206-10. doi: 10.1080/09674845.2004.11732673.

Abstract

The over-expression of a new zinc ribbon (ZNRD1) gene has been shown previously to promote a multidrug-resistant phenotype in gastric cancer cells through the up-regulation of permeability-glycoprotein (P-gp). In the present study, siRNA eukaryotic expression vectors of ZNRD1 are constructed and transfected into SGC7901/VCR cells to examine whether or not down-regulation of ZNRD1 increases cell sensitivity towards chemotherapeutic drugs. After transfection, ZNRD1 expression decreased dramatically in ZNRD1 siRNA transfectants compared with that in parental cells and empty vector control cells. Down-regulation of ZNRD1 significantly enhanced the sensitivity of SGC7901/VCR cells to vincristine, adriamycin and etoposide, but not to 5-fluorouracil and cisplatin. Cell capacity to efflux adriamycin decreased markedly in ZNRD1 siRNA transfectants, and correlation between ZNRD1 down-regulation and increased multidrug resistance 1 (MDR1) gene transcriptional activity was observed. These results suggest that the ZNRD1 siRNA constructs down-regulate the expression of ZNRD1 effectively and reverse the resistant phenotype of gastric cancer cells. Furthermore, ZNRD1 might influence transcription of the MDR1 gene and thus play an important role in multidrug resistance in gastric carcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antineoplastic / analysis
  • Cell Line, Tumor
  • DNA-Binding Proteins / genetics*
  • Down-Regulation / genetics
  • Doxorubicin / analysis
  • Drug Resistance, Multiple / genetics
  • Humans
  • RNA, Neoplasm / genetics
  • RNA, Small Interfering / genetics*
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / genetics*

Substances

  • Antibiotics, Antineoplastic
  • DNA-Binding Proteins
  • POLR1H protein, human
  • RNA, Neoplasm
  • RNA, Small Interfering
  • Doxorubicin